Name: Pernilla Abrahamsson Education: PhD in medicine Age: 46 Family: Married, two teenagers Hobbies: We spend a lot of time in the cottage and the whole family goes cross-country skiing. It feels good to be creative like working with crafts or just try something new. Living: House in Ersmark, Umeå [...]
Lipum is attending two significant events in Vienna next week. At the RESI Europe and the BIO-Europe Spring meetings we will meet with key decision makers from the pharma and venture capital segments. These events take place March 25-27 and provides an opportunity to meet, please contact us and learn more about our unique approach [...]
On 6-7 March, Lipum attends a pitching event for Deep Tech companies in Stockholm hosted by The European Innovation Council (EIC) pilot and Nasdaq. The event is exclusively organised for EIC pilot- funded companies with the opportunity to pitch their business to top European investors and connect with Nasdaq representatives and partners. The 15 attending [...]
Tomorrow, Lipum will close a share issue raising SEK 25 million in addition to support from Horizon 2020 of SEK 23 million grant. The capital will finance the preclinical work and the development of a production method up to the start of toxicology studies next year. See the full interview (in swedish) from BioStock [...]
At this event we will present the progress of our unique and EU Horizon 2020 supported approach for treatment of chronic inflammatory diseases. In addition, it will also be an opportunity to learn more about Orexo with a market cap of SEK 2.6 billion. Surprisingly, the brilliant Swedish pop group Torsson will be represented. In [...]
Thursday 7th February we will spend with potential investors and partners together with 14 participating companies from Umeå. It's the annual Biotech Umeå Investment Day 2019. We are looking forward to this event since we are at the stage of finding investors for our exciting progress towards a new drug against chronic inflammatory diseases. We [...]
According to Johnson & Johnson there are still tons of opportunity in the immunology market, even though it´s crowded. Jennifer Taubert, executive vice president and worldwide pharma chairman recently said at the J.P. Morgan Healthcare Conference: “We do look at immunology as being very, very attractive, and in certain areas, there’s so much unmet medical [...]
Being a European Commission Horizon 2020 beneficiary has a distinct positive impact on our development. The 2.2 M€ grant enables us to proceed faster towards a new drug against chronic inflammatory diseases. To further increase the momentum we are now raising additional funding by a share issue. Interested investors get a chance to join the [...]
A range of CMO partners have been evaluated for cell line development and production of Lipum’s antibody. Next weeks our CEO and CMC Project Manager will travel to both Europe and the US visiting contract manufacturers before selecting this critical collaboration partner. To be continued ...
An article from Biostock In the northern of Sweden, Umeå, the privately owned company Lipum wants to draw the game plan for the treatment of chronic inflammatory diseases. The main assets are a new drug candidate and promising preclinical result for a unique target molecule. BioStock has met CEO Einar Pontén and discussed the past year [...]